Skip to main content

Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome

Exciting news for the Angelman syndrome community! Ionis' Angelman syndrome program, ION582, has just shared positive preliminary results from the Phase 1/2a HALOS clinical trial. Ionis will be providing an update at the upcoming Angelman Syndrome Foundation meeting in July, which will be streamed for those who cannot attend.

Read the community letter from Ionis here.

Read the Full Press release here.